[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol; 2010 Jun;17(3):37-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
  • QUESTION: What are the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in squamous cell carcinoma of the head and neck (HNSCC)?
  • Anti-EGFR therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab.
  • The most common histologic type is squamous cell carcinoma, and most common sites are the oral cavity, the oropharynx, the hypopharynx, and the larynx.
  • Worldwide, HNSCC is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor.
  • Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced (stages III-IVB) HNSCC; however, meta-analytic data indicate that the benefit of concurrent platinum-based chemotherapy disappears in patients over the age of 70 years.
  • Cetuximab is a monoclonal antibody approved for use in combination with radiation in the treatment of patients with untreated locally advanced HNSCC and as monotherapy for patients with recurrent or metastatic (stage IVC) HNSCC who have progressed on platinum-based therapy.
  • Given the interest in anti-EGFR agents in advanced HNSCC, the Head and Neck Cancer Disease Site Group (DSG) of Cancer Care Ontario's Program in Evidence-Based Care (PEBC) chose to systematically review the literature pertaining to this topic so as to develop evidence-based recommendations for treatment.
  • OUTCOMES: Outcomes of interest included overall and progression-free survival, quality of life, tumour response rate and duration, and the toxicity associated with the use of anti-EGFR therapies.
  • The randomized controlled trials (RCTS) involved three distinct patient populations: those with locally advanced HNSCC being treated for cure, those with incurable advanced recurrent or metastatic HNSCC being treated with first-line platinum-based chemotherapy, and those with incurable advanced recurrent or metastatic HNSCC who had disease progression despite, or who were unsuitable for, first-line platinum-based chemotherapy.
  • PRACTICE GUIDELINE: These recommendations apply to adult patients with locally advanced (nonmetastatic stages iii-ivb) or recurrent or metastatic (stage IVC) HNSCC.
  • Platinum-based chemoradiation remains the current standard of care for treatment of locally advanced HNSCC.
  • In patients with locally advanced HNSCC who are medically unsuitable for concurrent platinum based chemotherapy or who are over the age of 70 years (because concurrent chemotherapy does not appear to improve overall survival in this patient population), the addition of cetuximab to radical radiotherapy should be considered to improve overall survival, progression-free survival, and time to local recurrence.Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent or metastatic HNSCC, and is recommended to improve overall survival, progression-free survival, and response rate.The role of anti-EGFR therapies in the treatment of locally advanced HNSCC is currently under study in large randomized trials, and patients with HNSCC should continue to be offered clinical trials of novel agents aimed at improving outcomes.
  • However, five ongoing trials are investigating the effect of the addition of EGFR inhibitors concurrently with, before, or after chemoradiotherapy; those trials should provide direction about the best integration of cetuximab into standard treatment.
  • In patients with recurrent or metastatic HNSCC who experience progressive disease despite, or who are unsuitable for, first-line platinum-based chemotherapy, gefitinib at doses of 250 mg or 500 mg daily, compared with weekly methotrexate, did not increase median overall survival [hazard ratio (hr): 1.22; 96% confidence interval (ci): 0.95 to 1.57; p = 0.12 (for 250 mg daily vs. weekly methotrexate); hr: 1.12; 95% ci: 0.87 to 1.43; p = 0.39 (for 500 mg daily vs. weekly methotrexate)] or objective response rate (2.7% for 250 mg and 7.6% for 500 mg daily vs. 3.9% for weekly methotrexate, p > 0.05).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Jul;72(1):123-8 [7599040.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1796-807 [10974628.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30 [12422310.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):555-9 [12566295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54 [12909240.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 6:vi20-vi24 [15987992.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 [16050785.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):340-2 [16808060.001]
  • [Cites] J Dent Res. 2007 Feb;86(2):104-14 [17251508.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • (PMID = 20567625.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2880902
  • [Keywords] NOTNLM ; Head-and-neck cancer / egfr inhibitors / epidermal growth factor receptor / overall survival / progression-free survival / tumour response rate
  •  go-up   go-down


2. Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G: Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.). Anticancer Res; 2005 Nov-Dec;25(6C):4445-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
  • BACKGROUND: The combination of cisplatin (CDDP) and 5-Fluorouracil (5-FU) is a standard regimen for the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
  • This combination shows a relevant toxicity and new chemotherapy associations with a more favourable toxicity profile are awaited.
  • MATERIALS AND METHODS: Since 2001, a multicentre, phase II trial has been underway to evaluate the efficacy and toxicity of the CB+R combination in untreated patients with recurrent or metastatic HNSCC.
  • Patients had a histo/cytologically proven recurrent or metastatic HNSCC; patients with locally advanced disease not amenable to CDDP+5-FU treatment were also included.
  • Twelve patients were staged III and 20 were metastatic (10 recurrent).
  • The oral cavity/oropharynx were the primary site in 20 patients and the larynx in 10 patients.
  • The median time to progression was 4.2 months and median duration of survival was 9.8 months.
  • CONCLUSION: In our phase II trial, CB in combination with R showed a moderate activity with safe administration on an outpatient basis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334124.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; BG3F62OND5 / Carboplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


3. Ariyoshi Y, Miyatake S, Kimura Y, Shimahara T, Kawabata S, Nagata K, Suzuki M, Maruhashi A, Ono K, Shimahara M: Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep; 2007 Oct;18(4):861-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis.
  • The purpose of this clinical trial was to evaluate the utility of boron neutron capture therapy (BNCT) using epithermal neutrons for cases of recurrent cancer in the oral cavity, which are not indicated for a conventional treatment modality.
  • We enrolled four patients with local recurrence or metastasis to the regional lymph nodes after completion of initial treatments, including surgery, chemotherapy and radiotherapy.
  • Before receiving BNCT, patients underwent 18F-p-bononophenylalanine (BPA) positron emission tomography (PET) examinations to assess the BPA accumulation ratios in tumors and normal tissues.
  • Before BNCT, that patient could not be discharged from the hospital because of eating difficulties and malaise; after treatment, he was comfortably discharged.
  • Mild malaise, oral mucositis and alopecia were seen as mild adverse effects; however, no life-threatening systemic symptoms were observed in any of the cases.
  • Our results suggested that BNCT is a useful treatment modality for recurrent or regionally metastasized oral cancer.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Neutrons
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Boron Compounds / therapeutic use. Carcinoma, Mucoepidermoid / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Head and Neck Neoplasms / radiotherapy. Humans. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786347.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Boron Compounds
  •  go-up   go-down


Advertisement
4. Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K: Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol; 2007 Oct 20;25(30):4800-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
  • PURPOSE: Recurrent squamous cell carcinoma of the head and neck (SCCHN) or new second primary tumor (SPT) in a previous radiation field, if not curable by surgery or radiation, is almost always fatal.
  • Chemotherapy alone yields a median survival time (MST) of no more than 10 months and 1-year overall survival (OS) of 35% at best.
  • Concurrent reirradiation and chemotherapy is an alternative strategy.
  • PATIENTS AND METHODS: Eligibility for Radiation Therapy Oncology Group (RTOG) protocol 9911 stipulated recurrent SCCHN or SPT in a previous radiation field.
  • Patients received twice-daily radiation (1.5 Gy per fraction bid x 5 days every 2 weeks x4), plus cisplatin 15 mg/m2 intravenously (IV) daily x 5 and paclitaxel 20 mg/m2 IV daily x 5 every 2 weeks x4.
  • Oropharynx (40%) and oral cavity (27%) were the predominant primary sites.
  • Median prior radiation dose was 65.4 Gy.
  • Seventy-four percent of patients completed chemotherapy.
  • Eight treatment-related deaths (8%) occurred: five in the acute setting, three late (including two carotid hemorrhages).
  • CONCLUSION: Despite a high incidence of grade 5 toxicity, 1- and 2-year OS rates for split-course bid radiation therapy and concurrent cisplatin/paclitaxel exceed results generally seen with chemotherapy alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Paclitaxel / administration & dosage. Survival Rate


5. Agra IM, Carvalho AL, Pontes E, Campos OD, Ulbrich FS, Magrin J, Kowalski LP: Postoperative complications after en bloc salvage surgery for head and neck cancer. Arch Otolaryngol Head Neck Surg; 2003 Dec;129(12):1317-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only patients with recurrent head and neck squamous cell carcinoma undergoing en bloc salvage resection were eligible for the study.
  • RESULTS: The tumor location was the lip in 6 patients, oral cavity in 55, oropharynx in 31, larynx in 24, and hypopharynx in 8.
  • Previous treatment was surgery alone in 20 patients, radiotherapy alone in 68, surgery and radiotherapy in 21, and radiotherapy and chemotherapy in 14.
  • An additional patient received chemotherapy alone before salvage surgery.
  • The clinical stage of the recurrent tumor was I or II in 23 patients and III or IV in 101 patients.
  • The major factor associated with the overall occurrence of postoperative complications was the clinical stage of the recurrent tumor (P =.02).
  • The occurrence of minor complications correlated with the previously treated site, with complications occurring more often in patients undergoing locoregional vs local treatment (P =.04).
  • Major complications were associated with the time between initial treatment and salvage surgery (P =.05).
  • The clinical stage of the recurrent tumor and the previous site treated were the 2 major factors associated with the occurrence of postoperative complications.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Length of Stay / statistics & numerical data. Logistic Models. Male. Middle Aged. Morbidity. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14676158.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Kostrzewa JP, Lancaster WP, Iseli TA, Desmond RA, Carroll WR, Rosenthal EL: Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope; 2010 Feb;120(2):267-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer.
  • OBJECTIVES/HYPOTHESIS: To evaluate outcomes of salvage surgery with free flap reconstruction for recurrent squamous cell carcinoma of the oropharynx and oral cavity with increased use of chemoradiotherapy.
  • METHODS: All patients undergoing salvage surgery with free flap reconstruction for oropharynx (n = 36) and oral cavity (n = 36) squamous cell carcinomas between January 2001 and January 2008 were obtained.
  • RESULTS: Complications were more frequent in oropharynx than oral cavity tumors (36% and 14%, respectively; P = .05) requiring more secondary procedures (15 for oropharynx vs. six for oral cavity).
  • Median survival overall following salvage surgery was 44.8 months for oral cavity and 53.8 months for oropharynx head and neck squamous cell carcinoma.
  • CONCLUSIONS: Salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal tumors after chemoradiotherapy has acceptable morbidity and similar cure rates as salvage following radiotherapy without chemotherapy.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2007 Jan;29(1):26-32 [17103406.001]
  • [Cites] Head Neck. 2006 Feb;28(2):107-13 [16388526.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jan;136(1):98-103 [17210342.001]
  • [Cites] Laryngoscope. 2007 May;117(5):781-4 [17473668.001]
  • [Cites] Head Neck. 2008 Mar;30(3):281-8 [17764087.001]
  • [Cites] Head Neck. 2008 Nov;30(11):1422-30 [18767179.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 2 Suppl 93):1-18 [10714711.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5518-23 [18936479.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1998;10(3):155-60 [9704176.001]
  • [Cites] Laryngoscope. 2005 Apr;115(4):629-39 [15805872.001]
  • [Cites] Cancer. 2005 May 15;103(10):2073-81 [15816049.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3562-7 [15908667.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] Am J Clin Oncol. 2005 Aug;28(4):385-92 [16062081.001]
  • [Cites] Laryngoscope. 2007 Jan;117(1):16-21 [17202924.001]
  • (PMID = 20013840.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA142637; None / None / / R01 CA142637-02; United States / NCI NIH HHS / CA / R01 CA142637-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS258253; NLM/ PMC3389788
  •  go-up   go-down


7. Kovács AF, Eberlein K, Hülsmann T: Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus. Oral Maxillofac Surg; 2009 Jun;13(2):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
  • PURPOSE: Induction chemotherapy with Taxotere, cisplatin, and 5-fluororacil (TPF) was mainly used in hypopharyngeal and laryngeal cancer patients for larynx preservation.
  • This study aimed to assess feasibility and toxicity in oral cavity and maxillary sinus cancer patients.
  • PATIENTS AND METHODS: Between 2003 and 2008, 21 patients (18 male, three female; mean age 58 years; 15 patients Eastern Cooperative Oncology Group > or =1) suffering from advanced squamous cell cancers of the oral cavity (seven primaries, eight locoregional recurrences) and the maxillary sinus (six patients) were prospectively treated with three cycles of TPF (q3w) and were scheduled to undergo definitive chemoradiation.
  • Reasons for incomplete treatment were tumor progression, edema, seizure, bad general condition, sepsis, pneumonia (each once).
  • The infections led to two treatment-related deaths (9.5%).
  • Ten patients underwent a definitive chemoradiation or radiation (47.6%).
  • After a mean observation time of 17 months, nine patients are alive; one of them developed a local recurrence.
  • CONCLUSIONS: Chemotherapy with TPF is a highly effective treatment with considerable toxicity that needs special expertise which is best assured in a multidisciplinary setting.
  • Pretreated recurrent cancers demonstrated bad response.
  • A target for organ preservation could be the maxillary sinus; due to tumor regression in advanced oral tongue cancer, consecutively, a reduced function has to be encountered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Maxillary Sinus Neoplasms / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease Progression. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Opportunistic Infections / etiology. Pilot Projects. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Stomatitis / chemically induced. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2009 May;20(5):921-7 [19179556.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2873-8 [16782926.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):485-8 [12393990.001]
  • [Cites] Mund Kiefer Gesichtschir. 2006 May;10(3):168-77 [16604330.001]
  • [Cites] Oral Oncol. 2006 Aug;42(7):675-84 [16731029.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jun;136(6):1003-9 [17547996.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7 [15145166.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):585-90 [16739325.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):75-85, viii [15649500.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • (PMID = 19430823.001).
  • [ISSN] 1865-1550
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Taxoids; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; TPF protocol
  •  go-up   go-down


8. Kubota A, Furukawa M, Kawano T, Komatsu M: [Nedaplatin for recurrent cancer of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2004 May;107(5):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nedaplatin for recurrent cancer of the head and neck].
  • This study was undertaken to evaluate the clinical efficacy and toxicity of Nedaplatin (254-S) alone or combined for UFT for recurrent head and neck cancers in an outpatient setting.
  • Thirty-two patients, previously treated, (30 men and 2 women, mean age 59 years, twenty one with loco-regional recurrence and 11 with distant metastasis, 29 with squamous cell carcinoma, 2 with adenocarcinoma and one with adenoid cystic carcinoma) were treated with Nedaplatin (254-S) alone or combined with UFT.
  • The primary site was identified in the oropharynx in 8 patients, oral cavity in 7, larynx in 5, nasopharynx in 4, hypopharynx in 3, sinuses in one, parotid in one, and unknown primary in one patient.
  • The 254-S administration was repeated at 4 week intervals, and in some patients was combined with daily oral administration of 400 mg of UFT-E (tegafur-uracil enterogranules).
  • Treatment with 254-S alone or combined UFT-E could be conducted in an outpatient setting and was able to improve the overall survival rate for recurrent head and neck cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Middle Aged. Survival Rate. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15198007.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 8UQ3W6JXAN / nedaplatin; 1-UFT protocol
  •  go-up   go-down


9. Sagowski C, Jaehne M, Kehrl W, Hegewisch-Becker S, Wenzel S, Panse J, Nierhaus A: Tumor oxygenation under combined whole-body-hyperthermia and polychemotherapy in a case of recurrent carcinoma of the oral cavity. Eur Arch Otorhinolaryngol; 2002 Jan;259(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor oxygenation under combined whole-body-hyperthermia and polychemotherapy in a case of recurrent carcinoma of the oral cavity.
  • BACKGROUND: Previous studies have reported synergistic effects of combined hyperthermia and chemotherapy and/or irradiation.
  • Tumor response to irradiation and chemotherapy of well-oxygenated and vascularized tumors, in general, is superior to that of hypoxic tumors.
  • Therefore, tumor oxygenation is recognized as an important predictive factor in the therapy of malignant tumors.
  • Technically, the head-neck area remains outside the hyperthermia chamber during whole-body hyperthermia (WBH) as currently applied in a number of cancer treatment regimens.
  • The aim of this therapeutic approach was to evaluate whether the blood flow during WBH also increased in the head-neck region and, if so, whether tumor oxygenation increase accordingly.
  • METHODS: A 60-year-old male Caucasian patient, with the original diagnosis of pT3 pN2b M0 squamous cell carcinoma of the oral cavity, who had undergone primary surgery and irradiation (total dose 60 Gy), developed three local recurrences with consecutive surgical resection, presenting now with another recurrent local tumor (histologically confirmed) without surgical or radiotherapeutical options due to lymphangiosis carcinomatosa.
  • WBH was applied under full anaesthesia, using a humidified radiant heat device (Enthermics Medical Systems RHS-7500) in combination with synchronous application of chemotherapy (ifosfamide and carboplatin).
  • Four cycles of this combined treatment (one cycle per month) were given.
  • Tumor oxygenation and temperature were continuously monitored by Licox catheters by means of one point measurement during each treatment (3.5 h).
  • RESULTS: With a latency of 10 min, the increase of intratumoral temperature in the oral cavity was comparable to reference values in the esophagous.
  • Maximum intratumoral temperature (oral cavity) was 41.8 degrees C (F).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Hyperthermia, Induced. Mouth Neoplasms / therapy. Oxygen / metabolism
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Partial Pressure

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11954922.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


10. Kasperts N, Slotman B, Leemans CR, Langendijk JA: A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol; 2005 Mar;41(3):225-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review on re-irradiation for recurrent and second primary head and neck cancer.
  • The purpose of this paper is to review the results of studies regarding radiation as primary or adjuvant treatment modality for head and neck recurrences or second primary tumours (SPT) in previously irradiated areas, with emphasis on acute and late radiation induced morbidity, locoregional control and survival.
  • (1) re-irradiation for locoregional recurrent disease or SPT in the head and neck region, (2) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx, and (3) a minimum of 10 patients included in the study.
  • Studies were divided in four categories, including (1) external beam re-irradiation, (2) re-irradiation with brachytherapy, (3) re-irradiation in combination with chemotherapy and (4) postoperative re-irradiation.
  • Most studies were retrospective using heterogeneous treatment regimens and including heterogeneous groups of patients.
  • High dose reirradiation as salvage treatment in case of recurrent or second primary head and neck cancer should be considered, particularly when salvage surgery is not feasible.
  • Although long term survivors are reported is some studies, the relatively high incidence of treatment-related morbidity emphasize the need for further optimisation in order to improve locoregional control and reduce the risk on late morbidity.
  • [MeSH-minor] Brachytherapy. Combined Modality Therapy. Humans. Morbidity. Retreatment. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oral Oncol. 2005 Oct;41(9):953-4 [15935725.001]
  • (PMID = 15743686.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


11. Sher DJ, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB: Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer; 2010 Oct 15;116(20):4761-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
  • BACKGROUND: Patients with locally recurrent squamous cell cancer of the head and neck (SCCHN) are reported to have a poor prognosis and limited therapeutic options.
  • This study reported the experience of the Dana-Farber Cancer Institute (DFCI) with IMRT-based chemoradiotherapy with or without surgery for locally recurrent SCCHN.
  • METHODS: The current study was a retrospective study of all patients treated at DFCI who were diagnosed with nonmetastatic second primary or recurrent SCCHN and who received reirradiation based on IMRT.
  • Recurrent disease was treated in the oral cavity (4 patients), larynx/hypopharynx (13 patients), oropharynx (7 patients), nasopharynx (2 patients), and neck (9 patients).
  • The median radiation dose was 60 Gray (Gy), and all patients received concurrent chemotherapy.
  • Approximately 91% and 46%, respectively, of all patients developed at least 1 acute and late grade 3 toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Retreatment. Retrospective Studies. Survival Analysis


12. Agra IM, Carvalho AL, Ulbrich FS, de Campos OD, Martins EP, Magrin J, Kowalski LP: Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck; 2006 Feb;28(2):107-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer.
  • BACKGROUND: Therapeutic decisions in recurrent oral and oropharyngeal squamous carcinoma (SCC) remain controversial.
  • METHODS: Two hundred forty-six consecutive patients who underwent salvage surgery for recurrent squamous cell carcinoma (SCC) of the oral cavity and oropharynx were studied.
  • The tumor sites were lip, 33 cases; oral cavity, 143; oropharynx, 70.
  • The previous treatment was surgery in 73 patients, radiotherapy in 96, combined surgery and radiotherapy in 76, and chemotherapy in one.
  • CONCLUSION: Patients with recurrent oral and oropharyngeal SCC at initial clinical stages (rCS I and II) and with a DFI greater than 1 year had a favorable prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Oropharyngeal Neoplasms / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc.
  • (PMID = 16388526.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Sagowski C, Kehrl W, Hegewisch-Becker S, Wenzel S, Jaehne M, Panse J, Nierhaus A: [Tumor oxygenation in combined whole body hyperthermia and polychemotherapy. Studies exemplified by recurrent carcinoma of the mouth cavity]. HNO; 2000 Dec;48(12):949-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor oxygenation in combined whole body hyperthermia and polychemotherapy. Studies exemplified by recurrent carcinoma of the mouth cavity].
  • [Transliterated title] Tumoroxygenierung unter kombinierter Ganzkörperhyperthermie und Polychemotherapie. Untersuchungen am Beispiel eines Rezidivkarzinoms der Mundhöhle.
  • BACKGROUND AND OBJECTIVE: Previous studies have reported synergistic effects of combined hyperthermia and chemotherapy and/or irradiation.
  • The response to irradiation and chemotherapy of well-oxygenated and vascularized tumors generally is better than that of hypoxic tumors.
  • Therefore, tumor oxygenation is recognized as an important predictive factor in the therapy of malignant tumors.
  • PATIENTS/METHODS: Whole-body hyperthermia, as heat radiation (Enthermics Medical Systems RHS-7500), was applied to the narcotised 60-year-old male patient with a local recurrence tumor pT3 pN2b M0 squamous cell carcinoma of the oral cavity.
  • Tumor oxygenation and temperature were measured by LICOX catheters via one-point measurement during the entire hyperthermia treatment (3.5 h).
  • Parallelly, chemotherapy (ifosfamide/Carboplatin) was given in four cycles (one cycle/month).
  • RESULTS: With a latency of 10 min the increase of intratumoral temperature was comparable to temperatures achieved in the esophagus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / blood supply. Cell Hypoxia / physiology. Hyperthermia, Induced / instrumentation. Mouth Neoplasms / blood supply. Neoplasm Recurrence, Local / blood supply
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11196098.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D; 2007;8(3):176-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
  • Introgen and its wholly owned European subsidiary Gendux AB are developing an adenoviral p53 gene therapy as a treatment for cancer in the US and Europe, respectively.
  • INGN 201 is being reviewed by the EMEA for approval in Li-Fraumeni syndrome (LFS) under the provisions of exceptional circumstance; the therapy is available on a compassionate use basis to eligible LFS cancer patients under a protocol authorised by the US FDA.
  • The p53 protein is one of the most intricate elements in the apoptotic signalling cascade, and a mutation in the gene encoding it is believed to result in a decreased ability of a cell to apoptose.
  • Thus replacing this gene via adenovirally-mediated p53 gene therapy is hoped to result in increased apoptosis where it is administered.INGN 201 is available for licensing, although Introgen favours retaining partial or full rights to the therapy in the US.
  • Introgen entered into a collaboration with Rhône-Poulenc Rorer Pharmaceuticals (now sanofi-aventis) to develop therapeutics based on p53 inhibition in October 1994.
  • The second is for the combination of INGN 201 and standard chemotherapy, compared with standard chemotherapy alone, in 288 patients with recurrent squamous cell carcinoma of the head and neck.
  • Introgen expects to complete regulatory filings for advanced recurrent head and neck cancer in the US and EU within 2007.
  • Favourable phase II data of INGN 201 in a subpopulation of patients with recurrent, unresectable head and neck cancer (SCCHN) prompted Introgen to seek accelerated approval for INGN 201 in December 2004.
  • Introgen had presented combined results from three multicentre (US and Europe) phase II studies of INGN 201 in 217 patients with recurrent squamous cell carcinoma of the head and neck confirming previous safety and efficacy results of the treatment.
  • In April 2004, the Southwest Oncology Group initiated a similar clinical trial using INGN 201 for the treatment of stage III or IV squamous cell carcinoma of the oral cavity, or oropharynx, that is able to be removed surgically.
  • The study assessed the feasibility, efficacy and safety of administering INGN 201 at the time of surgery for suppression of remaining tumour cells, followed by a combination of chemotherapy and radiation therapy.
  • The previous trial was a phase II study that afforded Introgen access to surgical specialists in cancer and complemented the company's ongoing pivotal phase III studies in advanced recurrent disease.
  • In September 2003, INGN 201 was granted designation as a Fast Track Drug Product development programme by the FDA for prolonging survival and delaying time to disease progression in patients with recurrent, unresectable squamous cell carcinoma of the head and neck.
  • Previously, in February 2003, INGN 201 received orphan drug designation from the FDA for head and neck cancer.
  • Phase I trials in the US for the treatment of non-small-cell lung cancer have been completed.
  • Sanofi-aventis (formerly Rhône-Poulenc Rorer Gencell) initiated phase II trials in the US, Europe and Canada for non-small-cell lung cancer.
  • Intratumoral injection of RPR/INGN 201 in patients with recurrent glioblastomas was safe and resulted in expression of the p53 protein.
  • Direct administration of RPR/INGN 201 to the lower airways of patients with bronchioalveolar cell lung carcinoma resulted in symptomatic improvement and improved lung function in some patients.
  • In November 2003, according to a Clinical Trials Agreement between the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) and Introgen, a 6-month phase I/II study with p53 gene therapy administered in the form of an oral rinse or mouthwash for patients with oral premalignancies has been initiated.
  • This is the first trial to investigate the effect of this treatment on oral lesions that are at high risk for developing into full blown cancers.
  • In September 2006, the EMEA granted orphan drug status to INGN 201 for the treatment of LFS, following Gendux's application for the designation.
  • The company intends to provide the therapy on a compassionate use basis to qualifying patients in Europe.INGN 201 has been successfully used in the treatment of a LFS patient on a compassionate use basis under a protocol authorised by the FDA.
  • Based on these interim findings, Introgen has decided to continue making the therapy available through a compassionate use programme to eligible LFS patients who have relapsed after standard treatment as part of physician-sponsored protocols at qualifying institutions in the US.A worldwide, exclusive license to a family of US patents covering a combination therapy comprised of INGN 201 in combination with several inhibitors of epidermal growth factor receptors (EGFr) such as Erbituxtrade mark Vectibixtrade mark and Tarcevatrade mark was granted to Introgen by The University of Texas MD Anderson Cancer Center in November 2006.
  • In February 2006, Introgen exclusively licenced a broad patent (US Patent No. 6 989 375), originally issued to to the Board of Regents of The University of Texas System; the patent covers any therapeutic gene-based therapy when applied in combination with conventional cancer therapy such as radiation or chemotherapy.
  • Introgen Therapeutics was awarded a patent from the US Patent and Trademark Office in June 2005 that directly covers many of the special features of its INGN 201 molecular therapy.
  • US Patent No. 6,905,873 is one of a family of patents that cover INGN 201 that have been issued to the Board of Regents of The University of Texas System and exclusively licensed to Introgen.
  • To date, Introgen controls 30 issued patents relevant to the product covering compositions, therapeutic methods of administering the product in virtually any form, alone and in conjunction with the most widely used chemotherapeutic and radiation treatments, as well as its production, and has a large number of pending patent applications in the US and in foreign countries relating to its ADVEXIN((R)) therapy.
  • This patent extends Introgen's patent coverage for its adenoviral p53 gene therapy product to the year 2021, not taking into account possible patent extensions.
  • In February 2003, the US Patent and Trademark Office issued patent No. 6,511,847, entitled Recombinant p53 Adenovirus Methods and Compositions, covering any adenoviral DNA molecule that encodes the p53 gene positioned under the control of a promoter.US patents issued in 2002 include Patent No. 6,410,010, broadly covering all adenoviral p53 compositions (including ADVEXIN((R))) that express adequate p53 in amounts sufficient to suppress the growth of or kill cancer cells in patients.
  • The patent also covers adenoviral p53, which incorporates a specific type of promoter that helps cells to express the p53 tumour suppressor gene.
  • Introgen has a number of US patents that relate to the clinical use of adenoviral p53 gene therapy in cancer as monotherapy or in combination with one or more chemotherapeutic drugs, radiation therapies or other agents that have a damaging effect on the DNA or survival of (i.e.
  • 2-methoxyestradiol, Patent No. 6,410,029) cancer cells.A patent with broad claims directed to combination therapy with the p53 gene and conventional chemotherapy or radiation was issued in China in August 2005. Patent No.
  • [MeSH-major] Adenoviridae / genetics. Genes, p53. Genetic Therapy. Neoplasms / therapy. Viral Vaccines / therapeutic use


15. Massa E, Dessì M, Gaspardini G, Saba F, Cherchi V, Mantovani G: Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncol; 2010 Nov;46(11):818-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
  • The aim of the present study was to identify a potentially effective new treatment regimen for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck in disease progression after at least two previous chemotherapy regimens.
  • The regimen was administered to patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with surgery, radiotherapy or both and progressing after at least two chemotherapy regimens.
  • Twenty-four patients with histologically confirmed tumors of oral cavity, oropharynx, hypopharynx and larynx were enrolled.
  • After 3 cycles of treatment 23 patients (95.8%) were evaluable for response: 4 patients had partial response; 12 stable disease and 7 progressive disease.
  • The present study shows that the combination of Vinorelbine and Cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck patients is effective, feasible and has a good safety profile.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20920877.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 5V9KLZ54CY / Vinblastine; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


16. Martínez-Monge R, Gómez-Iturriaga A, Cambeiro M, Garrán C, Montesdeoca N, Aristu JJ, Alcalde J: Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer. Brachytherapy; 2009 Jan-Mar;8(1):26-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer.
  • BACKGROUND: To determine the feasibility of combined perioperative high-dose-rate brachytherapy (PHDRB) and intermediate-dose external beam radiation therapy (EBRT) as an alternative to full-dose adjuvant EBRT in patients with unirradiated squamous cell cancer (SCC) of the oral cavity and oropharynx.
  • Patients with Stage III, IVa tumors, and some recurrent cases received concomitant cisplatin-paclitaxel chemotherapy during EBRT.
  • Eleven patients (27.5%) developed RTOG Grade 3 or greater toxicity.
  • Four patients (10%) presented complications requiring a major surgical procedure (RTOG 4), and one patient died of bleeding (RTOG 5).
  • Three complications (7.5%) occurred in the perioperative period, and 8 (20.0%) occurred more than 3 months after the completion of the treatment program.
  • CONCLUSIONS: PHDRB can be integrated into the management of patients with resected cancer of the oral cavity who are candidates to receive postoperative radiation or chemoradiation.
  • [MeSH-major] Brachytherapy / adverse effects. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Oropharyngeal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041280.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Karakoyun-Celik O, Norris CM Jr, Tishler R, Mahadevan A, Clark JR, Goldberg S, Devlin P, Busse PM: Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base. Head Neck; 2005 May;27(5):353-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base.
  • BACKGROUND: The purpose of this study was to examine the long-term outcome of a cohort of patients with unresected base of tongue carcinoma who received interstitial brachytherapy after comprehensive external beam radiation therapy.
  • METHODS: Between 1983 and 2000, 122 patients with primary or recurrent squamous cell carcinoma of the oropharynx or oral cavity received interstitial brachytherapy as part of their overall management.
  • Forty patients had primary, unresected carcinoma of the base of tongue and are the subjects of this analysis.
  • Twenty-four (60%) received two to three cycles of neoadjuvant chemotherapy.
  • The oropharynx, bilateral neck, and supraclavicular fossae were comprehensively irradiated, and the tongue base received a median external beam dose of 61.2 Gy (50-72 Gy).
  • The primary site was then boosted with an interstitial 192Iridium implant by use of a gold-button single-strand technique and three-dimensional treatment planning.
  • The dose rate was prescribed at 0.4 to 0.5 Gy/hr.
  • The median implant dose was 17.4 Gy (9.6-24 Gy) and adjusted to reach a total dose to the primary tumor of 80 Gy.
  • N2 to 3 disease was managed by a planned neck dissection performed at the time of the implant.
  • The overall survival and primary site control were independent of T classification, N status, or overall stage.
  • Systemic therapy was associated with an improvement in overall survival (p = .04) and a trend toward increased primary site control with greater clinical response.
  • CONCLUSIONS: In an era of greatly improved dose distributions made possible by three-dimensional treatment planning and intensity-modulated radiation therapy, brachytherapy allows a highly conformal dose to be delivered in sites such as the oropharynx.
  • If done properly, the procedure is safe and delivers a dose that is higher than what can be achieved by external beam radiation alone with the expected biologic advantages.
  • This approach has led to a 78% rate of organ preservation at 5 years, with a 5% incidence of significant late morbidity (osteonecrosis) that has required medical management.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Squamous Cell / therapy. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Iridium Radioisotopes / therapeutic use. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Computer-Assisted. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley Periodicals, Inc.
  • (PMID = 15726587.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


18. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ: Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Semin Radiat Oncol; 2004 Apr;14(2):190-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck.
  • Despite advances in our ability to safely treat patients with recurrent cancer of the upper aerodigestive tract, outcomes for retreatment are generally poor and the first chance to cure these patients remains the best chance.
  • Thorough knowledge of the outlook and options for patients with recurrent disease is also of significance in choosing therapy for patients with newly diagnosed disease.
  • This is especially true for newly diagnosed patients making the choice between surgery and nonsurgical ("organ-sparing") options, who need to know the outlook for salvage surgery, should they recur after radiation with or without concomitant chemotherapy.
  • Salvage surgery is generally the best option for previously irradiated patients who are faced with resectable, recurrent disease.
  • Unfortunately, the results of surgical salvage are generally poor for patients with advanced stage recurrence and for those who recur after treatment of advanced disease.
  • The site of initial and recurrent disease is important.
  • Surgical salvage is most effective for patients with recurrent laryngeal cancer, least effective for recurrent cancer of the pharynx, and is intermediate for recurrence in the oral cavity.
  • Patients choosing nonsurgical treatment for newly diagnosed cancer of the pharynx cannot rely on salvage surgery in the event of recurrence.
  • Reirraditation for patients who have failed initial treatment that included radiation therapy has been used at a number of institutions with some success.
  • Experience using reirradiation with or without concomitant chemotherapy continues to evolve.
  • Palliative chemotherapy is an option for most patients, but response rates are generally poor and of short duration, after failure of initial treatment that includes radiation therapy.
  • The best approach for many patients and families who face advanced recurrent disease is honest but compassionate communication and supportive care with the help of a hospice organization.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Humans. Retreatment / methods. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15095264.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


19. Andreadis C, Vahtsevanos K, Sidiras T, Thomaidis I, Antoniadis K, Mouratidou D: 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol; 2003 Jun;39(4):380-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer.
  • The benefit of the effect of chemotherapy in patients with advanced head and neck squamous cell tumors have been demonstrated by recent meta-analyses of randomized studies.
  • However, the role of chemotherapy-especially in advanced oral cancer-is not fully clear, because of the very small amount of phase II literature available.
  • From January 1994 to December 2000, a total of 44 pts aged 33-75 years (mean age 60 years) with advanced and histologically proved squamous cell carcinoma's of the oral cavity received at least one chemotherapy course.
  • The chemotherapy was the initial therapy in a group of 21 patients.
  • In a second group of 23 patients the chemotherapy was delivered after relapse of their disease.
  • The pre-chemotherapy treatment of the second group was radiotherapy in 11, surgery in 4, combination of radiotherapy and surgery in 8 patients.
  • The chemotherapy regimen consisted of cisplatin 100 mg/m(2) in 3-h infusion, day 1 and 5-FU 1000 mg/m(2) in 24-h infusion, days 1-5.
  • Treatment was repeated every 21 days.
  • A total of 154 treatment courses (3.5 per patient, ranged 1-10) were administered.
  • Myelotoxicity, nausea and vomiting were the major treatment complications.
  • The overall response rate to the induction chemotherapy was 52.3%, with 19% complete (CR), and 33.3% partial response's (PR) and to the chemotherapy for recurrent/metastatic disease 30.4% with 8.7% CR, and 21.7% PR.
  • Chemotherapy with cisplatin and 5-FU combination is effective in pts with advanced squamous cell oral cancer and appears to improve the survival of patients who have a good response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Patient Selection. Retrospective Studies. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Science Ltd.
  • (PMID = 12676258.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Wutzl A, Ploder O, Kermer C, Millesi W, Ewers R, Klug C: Mortality and causes of death after multimodality treatment for advanced oral and oropharyngeal cancer. J Oral Maxillofac Surg; 2007 Feb;65(2):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality and causes of death after multimodality treatment for advanced oral and oropharyngeal cancer.
  • PURPOSE: To analyze mortality and causes of death in patients who received preoperative radiochemotherapy and underwent radical surgery for advanced oral or oropharyngeal cancer.
  • PATIENTS AND METHODS: A total of 222 patients who underwent multimodality treatment from 1990 to 2000 were included in the study.
  • Patients received preoperative radiotherapy 50 Gy and concomitant chemotherapy with mitomycin and 5-fluorouracil.
  • Although 93% of deaths related to recurrent disease occurred within the first 36 months after surgery, the remaining causes of death did not reveal a specific temporal pattern.
  • CONCLUSION: Favorable survival data were registered for patients with advanced squamous cell carcinoma of the oral cavity who underwent combined treatment protocols.
  • Because recurrent disease is a less common cause of mortality than are other causes, the latter should receive attention during surveillance.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy
  • [MeSH-minor] Cause of Death. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasms, Second Primary / mortality. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / surgery. Oropharyngeal Neoplasms / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236930.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Schwartz GJ, Mehta RH, Wenig BL, Shaligram C, Portugal LG: Salvage treatment for recurrent squamous cell carcinoma of the oral cavity. Head Neck; 2000 Jan;22(1):34-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage treatment for recurrent squamous cell carcinoma of the oral cavity.
  • BACKGROUND: Squamous cell carcinoma (SCCA) of the oral cavity recurs with a frequency of 25%-48%, a fact that usually portends a poor prognosis.
  • Investigators have also claimed that restaging recurrent tumors provides useful prognostic information, although this has not been demonstrated with tumors of the oral cavity.
  • (1) to report the patterns of recurrent SCCA of the oral cavity;.
  • (2) to examine the benefit of restaging oral cavity tumors, and (3) to compare different treatment modalities in the management of recurrent SCCA of the oral cavity.
  • Materials and Methods Thirty-eight patients who developed recurrent SCCA of the oral cavity were reviewed.
  • Salvage treatment consisted of surgery, chemotherapy, radiation therapy, or a combination of these modalities.
  • Survival analysis was based on the stage of the primary and recurrent tumors and the type of salvage treatment received.
  • Patients who recurred more than 6 months after completion of their primary treatment had improved survival compared with those who recurred within 6 months of initial treatment.
  • Individuals with stage I-II primary tumors had significantly improved salvage time and total survival time compared with those with stage III-IV primary tumors (p < 0.005 and p < 0.001).
  • Conversely, the stage of the recurrent tumor was not predictive of either improved salvage time or total survival time.
  • Patients who underwent salvage surgery had significantly improved salvage time and total survival time compared with those who received chemotherapy and/or radiation therapy (p < 0.001 and p < 0.002).
  • Neither the stage of the primary or recurrent tumors nor the type of salvage treatment received significantly correlated with an improved cure rate.
  • CONCLUSIONS: Squamous cell carcinoma of the oral cavity is most likely to recur at the primary site.
  • The stage of the primary tumor is significantly correlated with survival even after recurrence, but the stage of the recurrent tumor is not significantly correlated with survival.
  • Patients most likely to benefit from retreatment are those who (1) have primary tumors stage I-II, (2) recur greater than 6 months after their initial treatment, and (3) develop recurrences that are amenable to salvage surgery.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Mouth Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Evaluation Studies as Topic. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Registries. Survival Rate. Treatment Outcome


22. Porceddu SV, Campbell B, Rischin D, Corry J, Weih L, Guerrieri M, Grossi M, Peters LJ: Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys; 2004 Oct 1;60(2):365-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma.
  • PURPOSE: To describe the use of postoperative concurrent chemoradiotherapy, with either weekly cisplatin or carboplatin, for high-risk head-and-neck squamous cell carcinoma (HNSCC) in a single institutional setting.
  • The predominant primary site was the oral cavity in 24 patients (51%), 27 had nodal disease with extracapsular extension, and 26 had positive or close mucosal margins (<5 mm).
  • Ten patients had undergone resection of recurrent disease after previous surgery.
  • The median radiotherapy dose was 60 Gy (range, 50-66 Gy).
  • Of the 47 patients, 45 (96%) completed at least four of the six planned doses of chemotherapy and 45 (96%) completed the planned course of radiotherapy.
  • No treatment-related deaths occurred.
  • Five cases of Grade 3-4 late treatment-related sequelae developed.
  • CONCLUSION: Treatment with postoperative concurrent weekly cisplatin or carboplatin and radiotherapy was reasonably well tolerated.
  • Patients treated after resection of recurrent disease (after previous surgery alone) fared worse than those treated at the initial resection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Confidence Intervals. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neck Dissection. Radiation Injuries / etiology. Radiotherapy Dosage. Regression Analysis. Survival Rate


23. Mesía R, Palmero R, Cos M, Vilajosana E, Vázquez S: Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report. Head Neck Oncol; 2010;2:3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.
  • BACKGROUND: Symptom control is an important consideration in the choice of treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
  • Patients who demonstrate objective tumour responses to platinum-based chemotherapy are more likely to have symptom relief than those who do not have such responses.
  • A phase III trial (EXTREME) showed that adding the epidermal growth factor receptor (EGFR)-targeting IgG1 monoclonal antibody cetuximab to first-line platinum-based chemotherapy significantly prolongs progression-free and overall survival and increases response rate compared with platinum-based chemotherapy alone.
  • We report here the case of a 60-year old female with recurrent squamous cell carcinoma of the gum who had rapid palliation of symptoms and reduction of facial disease mass following treatment with a combination of carboplatin/5-fluorouracil (5-FU) and cetuximab.
  • CASE PRESENTATION: The patient was diagnosed with T4N0 M0 disease of the oral cavity in November 2006 and underwent surgery, with R0 resection, followed by adjuvant radiotherapy and concomitant cisplatin chemotherapy.
  • The patient received 4 21-day cycles of carboplatin (AUC 5), 5-FU (1,000 mg/m2/day for 4 days) and cetuximab (400 mg/m2 initial dose followed by subsequently weekly doses of 250 mg/m2), with continuation of cetuximab monotherapy at the end of this time, and pain relief with topical fentanyl and oral morphine.
  • After 7 days of treatment, pain had reduced to 2/10, with discontinuation of morphine after 4 days, and the facial mass had reduced to 70 mm.
  • After 2 cycles of treatment, the facial mass had decreased to 40 mm.
  • After 3 cycles of treatment, pain and facial oedema had resolved completely and a cervical computed tomography scan showed a marked reduction in tumour mass.
  • CONCLUSION: This case illustrates the rapid reduction of tumour mass and disease-associated pain and oedema that can be achieved with a combination of platinum-based chemotherapy and cetuximab in recurrent and/or metastatic SCCHN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2653-8 [16763279.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3562-7 [15908667.001]
  • [Cites] Ann Oncol. 1997 May;8(5):445-9 [9233523.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1135-41 [8758243.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • (PMID = 20181021.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2832769
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down






Advertisement